
Grazia Pennisi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2163951/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2022, 6, 1032-1044.	4.3	6
2	A cholestatic pattern predicts major liverâ€related outcomes in patients with nonâ€alcoholic fatty liver disease. Liver International, 2022, 42, 1037-1048.	3.9	4
3	Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 806-815.e5.	4.4	90
4	<i>PCSK9</i> rs11591147 R46L lossâ€ofâ€function variant protects against liver damage in individuals with NAFLD. Liver International, 2021, 41, 321-332.	3.9	26
5	Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. Gastroenterology, 2021, 160, 1634-1646.e7.	1.3	82
6	Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C. Minerva Gastroenterology, 2021, 67, 254-263.	0.5	2
7	Interplay between nonâ€alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2389-2396.	2.8	6
8	<i>NR1H4</i> rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. Liver International, 2021, 41, 2712-2719.	3.9	6
9	PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1979-1981.	4.4	10
10	Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2021, 75, 786-794.	3.7	100
11	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 935-944.e3.	4.4	102
12	The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2020, 26, 3928-3938.	1.9	3
13	Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.		1
14	Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. International Journal of Environmental Research and Public Health, 2019, 16, 4334.	2.6	21
15	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2310-2319.e6.	4.4	66
16	Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. Pharmaceuticals, 2018, 11, 121.	3.8	41